Report cover image

Genitourinary Drugs Market Growth, Size, Trends Analysis - By Indication, By Product - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Feb 24, 2025
Length 230 Pages
SKU # SPER19912341

Description

Genitourinary Drugs Market Introduction and Overview

According to SPER market research, ‘Global Genitourinary Drugs Market Size- By Indication, By Product – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Genitourinary Drugs Market is predicted to reach 34.22 Billion by 2034 with a CAGR 1.39%.

Genitourinary drugs are used to treat conditions affecting the urinary and reproductive systems. These medications address a variety of issues, including infections, incontinence, erectile dysfunction, kidney stones, and prostate problems. For instance, antibiotics like trimethoprim-sulfamethoxazole are commonly prescribed for urinary tract infections (UTIs), while diuretics manage fluid retention in kidney or heart conditions.

Restraints: The high costs of drug development and treatment present a major challenge in the genitourinary drugs market, limiting both innovation and patient access. The need for extensive clinical trials and regulatory approvals increases expenses, with drugs like Enzalutamide costing over USD 1 billion to develop. These elevated costs make treatments unaffordable, particularly in low-income countries, restricting market reach.

Scope of the Report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Indication, By Product.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Abbott, Allergan, Antares Pharma, AstraZeneca, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline, Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, and others.

Genitourinary Drugs Market Segmentation:

By Indication: Based on the Indication, Global Genitourinary Drugs Market is segmented as; Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis, Haematuria, Benign Prostatic Hyperplasia.

By Product: Based on the Product, Global Genitourinary Drugs Market is segmented as; Urologicals, Hormonal Therapy, Gynecological, Anti-infectives, Others.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Table of Contents

230 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Genitourinary Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Genitourinary Drugs Market
7. Global Genitourinary Drugs Market, By Indication, (USD Million) 2021-2034
7.1. Prostate Cancer
7.2. Ovarian Cancer
7.3. Bladder Cancer
7.4. Cervical Cancer
7.5. Renal Cancer
7.6. Erectile Dysfunction
7.7. Urinary Tract Infections
7.8. Urinary Incontinence & Overactive Bladder
7.9. Sexually Transmitted Diseases
7.10. Interstitial Cystitis
7.11. Haematuria
7.12. Benign Prostatic Hyperplasia
8. Global Genitourinary Drugs Market, By Product, (USD Million) 2021-2034
8.1. Urologicals
8.2. Hormonal Therapy
8.3. Gynecological
8.4. Anti-infectives
8.5. Others
9. Global Genitourinary Drugs Market, (USD Million) 2021-2034
9.1. Global Genitourinary Drugs Market Size and Market Share
10. Global Genitourinary Drugs Market, By Region, (USD Million) 2021-2034
10.1. Asia-Pacific
10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada
10.4.2. Mexico
10.4.3. United States
10.5. Latin America
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America
11. Company Profile
11.1. Abbott
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Allergan
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Antares Pharma
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. AstraZeneca
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Bayer AG
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Bristol-Myers Squibb Co.
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Eli Lilly and Company
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. F. Hoffmann-La RocheLtd.
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Genentech, Inc.
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. GlaxoSmithKline
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Ionis Pharmaceuticals, Inc.
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. Merck & Co., Inc.
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. Novartis AG
11.13.1. Company details
11.13.2. Financial outlook
11.13.3. Product summary
11.13.4. Recent developments
11.14. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us